MARKET

TTNP

TTNP

Titan Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.570
0.000
0.00%
After Hours: 2.590 +0.02 +0.78% 16:56 06/11 EDT
OPEN
2.580
PREV CLOSE
2.570
HIGH
2.640
LOW
2.550
VOLUME
100.42K
TURNOVER
--
52 WEEK HIGH
13.35
52 WEEK LOW
2.150
MARKET CAP
25.35M
P/E (TTM)
-2.4766
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 06/04 12:11
Maxim Group Thinks Titan Pharmaceuticals’ Stock is Going to Recover
Maxim Group analyst Jason McCarthy assigned a Buy rating to Titan Pharmaceuticals (TTNP) yesterday and set a price target of $7.00. The company's shares
SmarterAnalyst · 05/04 14:33
The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15)
Benzinga · 04/16 12:00
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14)
Benzinga · 04/15 11:49
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13)
Benzinga · 04/14 11:51
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12)
Benzinga · 04/13 12:16
Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2020 with the Securities and Exchange Commission ("SEC").
PR Newswire · 03/31 20:30
10-K: TITAN PHARMACEUTICALS INC
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 03/31 20:15
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TTNP. Analyze the recent business situations of Titan Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TTNP stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 43
Institutional Holdings: 410.25K
% Owned: 4.16%
Shares Outstanding: 9.86M
TypeInstitutionsShares
Increased
6
105.82K
New
6
101.23K
Decreased
3
10.31K
Sold Out
2
5.50K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.92%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Marc Rubin
President/Chief Operating Officer/Chief Scientific Officer/Director
Katherine DeVarney
Independent Director
Joseph Akers
Independent Director
M. David MacFarlane
Lead Director
Seghi Recli
Independent Director
James McNab
Independent Director
Scott Smith
No Data
About TTNP
Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.

Webull offers kinds of Titan Pharmaceuticals, Inc. stock information, including NASDAQ:TTNP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTNP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TTNP stock methods without spending real money on the virtual paper trading platform.